CompletedEarly Phase 1NCT00601913

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Studying Squamous cell carcinoma of oral cavity and lip

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wake Forest University Health Sciences
Principal Investigator
Mercedes Porosnicu, MD, MD
Wake Forest University Health Sciences
Intervention
erlotinib hydrochloride(drug)
Enrollment
24 enrolled
Eligibility
18-120 years · All sexes
Timeline
20082014

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00601913 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of oral cavity and lip

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of oral cavity and lip

← Back to all trials